Open AccessCases in Precision Medicine: The Role of Tumor and Germline Genetic Testing in Breast Cancer Management
Author(s) -
Jonah L. Tischler,
Katherine D. Crew,
Wendy K. Chung
Publication year - 2019
Publication title -
annals of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.839
H-Index - 390
eISSN - 1539-3704
pISSN - 0003-4819
DOI - 10.7326/m18-2417
Subject(s) - genetic testing , medicine , breast cancer , precision medicine , personalized medicine , cancer , cancer screening , germline , risk assessment , personalization , intensive care medicine , family medicine , oncology , bioinformatics , pathology , genetics , gene , computer science , biology , world wide web , computer security
Personalization of care through precision medicine and, more specifically, genetic testing is altering the treatment of breast cancer. Genetic testing is used in germline and tumor testing, with each providing distinct data to guide management. Germline testing supports more accurate risk evaluation to inform screening and risk-reducing medical and surgical strategies. Tumor testing can inform cancer recurrence risk assessment and cancer treatment options. This article reviews how genetic testing informs treatment and potential risks for a patient with breast cancer and her family. Hereditary cancer genetic testing of family members should include a discussion of potential results, adverse effects, clinical management options, and insurance coverage and address concerns about privacy or discrimination. Genetic professionals are available to assist with educating, testing, and treating patients with increased cancer risk.